Dermatology Month in Review: April 2024
In this review of dermatology news in April, we highlighted several major stories on such topics as cutaneous reactions to COVID-19, topical versus oral minoxidil, and FDA news.
Stay updated with breaking news from After Previous. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
In this review of dermatology news in April, we highlighted several major stories on such topics as cutaneous reactions to COVID-19, topical versus oral minoxidil, and FDA news.
1. Progression-free survival was longer in the lazertinib group vs the gefitinib group (20.6 months vs 9.7 months, with HR 0.45), however, OS data were immature. 2. Treatment-related adverse events were similar across both groups, however, lazertinib had higher rates of parasthesia and pruritus but lower levels of ALT elevations and diarrhea. Evidence Rating Level:
Further analyses from the Phase 1/1b CHRYSALIS-2 study showed patients with osimertinib pre-treated EGFR-mutated lung cancer who have a MET positive...
Hubungan itu kian erat saat Raja Malaka menikahi putri Raja Majapahit - Nasional - Okezone Nasional